John Sweetenham, MD, PhD

Editorials by John Sweetenham, MD

Editorial

End games, Charles Nesbitt Wilson and cancer survivorship

HemOnc Today, September 10, 2016
John Sweetenham, MD
The movie Charlie Wilson’s War, based on the book of the same name by George Crile III, depicts the story of Charles Nesbitt Wilson. Wilson…
Editorial

Balancing hope and realism: It may be time to adjust the sails

HemOnc Today, August 10, 2016
John Sweetenham, MD
Events of recent weeks have kept the focus of the oncology community in the United States on President Barack Obama’s national cancer moonshot…
Editorial

ASCO: A mixed bag of positives, negatives, promises for the future

HemOnc Today, July 10, 2016
John Sweetenham, MD
In years past, I have avoided using my monthly editorial to provide a report from the ASCO Annual Meeting, partly because the content from the…
Editorial

It’s good to share, both in research and in life

HemOnc Today, June 10, 2016
John Sweetenham, MD
As I reflect on the ASCO Annual Meeting — specifically the new data presented and what I learned this year — I think of it as the…
Editorial

Restoring the home-field advantage

HemOnc Today, May 10, 2016
John Sweetenham, MD
In team sports, home-field advantage appears to be a real phenomenon. Although the exact causes are not clear — despite having been extensively…
Editorial

Value and P values

HemOnc Today, April 10, 2016
John Sweetenham, MD
Measuring value in cancer care is challenging. The day I wrote this column, I was in a meeting discussing what might be reasonable longitudinal…
EditorialPublication Exclusive

New data on late treatment effects should change physician–patient discussions

HemOnc Today, March 10, 2016
John Sweetenham, MD
Just over a year ago, my editorial for HemOnc Today focused on times when strongly held opinions can get in the way of an objective assessment of…
EditorialPublication Exclusive

Preparing for the journey to the moon

HemOnc Today, February 25, 2016
John Sweetenham, MD
The cancer challenge has received considerable and welcome attention in the media in recent months. Following word of increased funding for the NCI…
EditorialPublication Exclusive

Precision cancer care: The knowledge (and reality) gap

HemOnc Today, January 10, 2016
John Sweetenham, MD
Almost every day my email and regular mail have at least one article related to the growth of precision cancer care; the promise of genomics and…
EditorialPublication Exclusive

Given high stakes of cancer care, biosimilar debate requires an open mind

HemOnc Today, December 10, 2015
John Sweetenham, MD
In the last few months, I have followed the emerging debate about the use of biosimilars at a distance, but they have not impacted my clinical…